Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting

Harun Achmad, Yousif Saleh Ibrahim, Muataz Mohammed Al-Taee, Gamal A. Gabr, Muhammad Waheed Riaz, Shadia Hamoud Alshahrani, Andrés Alexis Ramírez-Coronel, Abduladheem Turki Jalil, Hendrik Setia Budi, Windi Sawitri, Malyutina Elena Stanislavovna, Jitendra Gupta

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


Cancer immunotherapy is proposed to eradicate tumors by stimulating host anti-tumor immunity through utilizing various therapeutic approaches. Cancer vaccines have become a promising approach for cancer immunotherapy among the proposed platforms, either alone or in combination with other therapeutic agents. Due to the suboptimal efficacy of cancer vaccines in clinical trials and the advent of nanotechnology in the biomedicine field, scientists developed nanoplatforms, such as various nanoparticles (NPs), cell-derived components, and nanocomplexes, to deliver vaccine components to target cells and tissues, thereby supporting their anti-tumor efficacy and minimizing adverse side effects. To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modulation of the structure of the vaccines, such as using DC-specific ligands, has attracted extensive interest. Here, we reviewed the various forms of nanovaccines in cancer therapy and their therapeutic effects; we highlighted the properties and functions of DCs as the main antigen-presenting cells in immune responses and focused on targeting DCs in developing nanovaccines.

Original languageEnglish
Article number109434
JournalInternational Immunopharmacology
Publication statusPublished - Dec 2022


  • Cancer immunotherapy
  • Cancer vaccine
  • Dendritic cells
  • Nanoplatforms
  • Nanovaccines


Dive into the research topics of 'Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting'. Together they form a unique fingerprint.

Cite this